{
    "clinical_study": {
        "@rank": "35221", 
        "arm_group": [
            {
                "arm_group_label": "Vilazodone", 
                "arm_group_type": "Experimental", 
                "description": "Vilazodone treatment.  Dosage will begin at 10mg/day and will be increased to 20mg/day after 1 week, and 40mg/day after two weeks (optional).  Dosage can be held steady or lowered at any time during the study as clinically indicated in the event of adverse effects.  Twelve weeks of treatment, total."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Pill placebo."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether Vilazodone (Viibryd), an SSRI and 5HT1a\n      receptor agonist, is effective in treating Adult Separation Anxiety Disorder over a 12-week\n      treatment course."
        }, 
        "brief_title": "Vilazodone for Separation Anxiety Disorder", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Separation Anxiety Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Anxiety Disorders", 
                "Anxiety, Separation", 
                "Mental Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "In this randomized clinical trial, 40 adults with a principal diagnosis of Adult Separation\n      Anxiety Disorder (ASAD) and no major depression or substance abuse disorders will be\n      randomized to 12 weeks of treatment with vilazodone (flexibly dosed) or matched pill\n      placebo. Outcome will be assessed in respect to symptomatic improvement, quality of life,\n      adverse events and safety."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Current primary (most clinically significant) diagnosis of DSM5 ASAD\n\n          -  Able to give consent, fluent in English\n\n        Exclusion Criteria:\n\n          -  Past or current DSM-IV diagnosis of any psychotic disorder; organic mental disorder\n             or other cognitive disorder; bipolar disorder; or antisocial personality disorder.\n             Current MDD of moderate or greater severity.  Any other current primary Axis I\n             disorder.\n\n          -  Recent history (past 3 months) of substance or alcohol abuse or dependence (other\n             than nicotine or caffeine)\n\n          -  Suicidal ideation or behavior (in the past year) that poses a significant danger to\n             the subject\n\n          -  Medical illness that could significantly increase risk of vilazodone treatment or\n             interfere with assessment of diagnosis or treatment response, including organic brain\n             impairment from stroke, CNS tumor, or demyelinating disease; renal impairment;\n             diabetes mellitus\n\n          -  Current or past history of seizure disorder (except febrile seizure in childhood)\n\n          -  History of non-response to \u2265 2 serotonergic reuptake inhibitor antidepressants (SSRIs\n             and/or SNRIs) for the treatment of ASAD after adequate treatment trials (adequate\n             treatment is defined as at least 8 weeks at an adequate dose[s] based on approved\n             package insert recommendations)\n\n          -  Currently taking medication which has been effective for patient's ASAD\n\n          -  For patients taking any ineffective psychoactive drug or herbal remedy, inability to\n             tolerate or unwillingness to accept a drug-free period prior to beginning the study\n             of 2 weeks or 5 half-lives (whichever is longer) before beginning study treatment, or\n             ever having been treated with a depot antipsychotic.  Fluoxetine washout period will\n             be at least 5 weeks.\n\n          -  Requiring concomitant treatment with any prohibited medications, supplements, or\n             herbal remedies, except for zolpidem, or zolpidem extended release for insomnia,\n             which may be continued provided the medication has been used in a consistent manner\n             for 4 weeks prior to randomization\n\n          -  History of intolerance or hypersensitivity to vilazodone, SNRIs or SSRIs\n\n          -  History of light therapy, electroconvulsive therapy, vagus nerve stimulation,\n             transcranial magnetic stimulation, or any other experimental procedure for central\n             nervous system disorders within 6 months of beginning this study\n\n          -  Pregnancy, lactation; for women of childbearing potential, not using an effective\n             birth control method (e.g., oral contraceptive or double barrier method) for the\n             duration of the study\n\n          -  Current formal psychotherapy initiated within 3 months of beginning this study.  This\n             includes: psychodynamic, cognitive-behavioral and interpersonal therapies"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01999920", 
            "org_study_id": "#6856"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vilazodone", 
                "description": "10mg to 40mg per day for 12 weeks", 
                "intervention_name": "Vilazodone", 
                "intervention_type": "Drug", 
                "other_name": "Viibryd (brand name)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "One to two pills per day for 12 weeks", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Adult separation anxiety disorder", 
            "ASAD"
        ], 
        "lastchanged_date": "January 23, 2014", 
        "location": {
            "contact": {
                "email": "valdovi@nyspi.columbia.edu", 
                "last_name": "Rob A. Valdovinos, BS", 
                "phone": "646-774-8113"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10032"
                }, 
                "name": "New York State Psychiatric Institute"
            }, 
            "investigator": {
                "last_name": "Franklin Schneier, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Vilazodone for Separation Anxiety Disorder", 
        "overall_contact": {
            "email": "Fschneier@nyspi.columbia.edu", 
            "last_name": "Franklin Schneier, MD", 
            "phone": "646-774-8041"
        }, 
        "overall_official": {
            "affiliation": "NYSPI", 
            "last_name": "Franklin Schneier, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Clinical Global Impression-Improvement Scale rating at week 12", 
            "measure": "Clinical Global Impression-Improvement Scale", 
            "safety_issue": "No", 
            "time_frame": "Week 12"
        }, 
        "reference": [
            {
                "PMID": "16741209", 
                "citation": "Shear K, Jin R, Ruscio AM, Walters EE, Kessler RC. Prevalence and correlates of estimated DSM-IV child and adult separation anxiety disorder in the National Comorbidity Survey Replication. Am J Psychiatry. 2006 Jun;163(6):1074-83. PubMed PMID: 16741209; PubMed Central PMCID: PMC1924723."
            }, 
            {
                "PMID": "1771219", 
                "citation": "Winslow JT, Insel TR. Serotonergic modulation of the rat pup ultrasonic isolation call: studies with 5HT1 and 5HT2 subtype-selective agonists and antagonists. Psychopharmacology (Berl). 1991;105(4):513-20."
            }, 
            {
                "PMID": "17447222", 
                "citation": "Simpson BS, Landsberg GM, Reisner IR, Ciribassi JJ, Horwitz D, Houpt KA, Kroll TL, Luescher A, Moffat KS, Douglass G, Robertson-Plouch C, Veenhuizen MF, Zimmerman A, Clark TP. Effects of reconcile (fluoxetine) chewable tablets plus behavior management for canine separation anxiety. Vet Ther. 2007 Spring;8(1):18-31."
            }, 
            {
                "PMID": "18974308", 
                "citation": "Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN, Sherrill JT, Ginsburg GS, Rynn MA, McCracken J, Waslick B, Iyengar S, March JS, Kendall PC. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008 Dec 25;359(26):2753-66. Epub 2008 Oct 30."
            }, 
            {
                "PMID": "11323729", 
                "citation": "[No authors listed] Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. N Engl J Med. 2001 Apr 26;344(17):1279-85."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01999920"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in Hamilton Depression Rating Scale 17-item total score", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 12 weeks"
            }, 
            {
                "measure": "change from baseline in Attachment Style Questionnaire score", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 12 weeks"
            }, 
            {
                "description": "Changes in Quality of Life Enjoyment & Satisfaction Questionnaire rating.", 
                "measure": "change from baseline in Quality of Life Enjoyment & Satisfaction Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 12 weeks"
            }, 
            {
                "description": "To note any side effects", 
                "measure": "change from baseline on Side Effect Checklist", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and 12 weeks"
            }, 
            {
                "measure": "change from baseline on Structured Clinical Interview for Separation Anxiety Disorder", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 12 weeks"
            }, 
            {
                "measure": "change from baseline on Adult Separation Anxiety - 27 Scale", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 12 weeks"
            }
        ], 
        "source": "New York State Psychiatric Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "Forest Laboratories", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "New York State Psychiatric Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}